© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Merck

FDA Approved stamp
FDA OKs Delstrigo and Pifeltro
Pharma CEOs Walk Into a Congressional Hearing to Defend High Prices
Switching to Merck’s Delstrigo Is Safe and Effective

Delstrigo

Pifeltro

Merck Files With FDA for Expanded Approval of Pifeltro and Delstrigo

An OK would add an indication for the use of these HIV medications among those switching from stable regimens.

2018 Top HIV Treatment Stories

Here are the HIV treatment news stories with the most views this year.

Older Tenofovir May Not Be Tied to Fracture Risk After All

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Treatment: Merck’s Doravirine

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

Picking Up the Pieces

The Impact of Hurricane Maria on HIV

Zepatier Zaps Acute Hep C in 8 Weeks

Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.

FDA Approves Merck’s Delstrigo and Pifeltro to Treat HIV

Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) includes Pifeltro (doravirine) in a three-drug single-tablet regimen.

All the AIDS Conference News That’s Fit to Print

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

Merck’s Experimental HIV Drug Doravirine Posts Promising 96-Week Results

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

Zepatier Beats Almost All Acute Hepatitis C in Just 8 Weeks

Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.

Prevention: Low-Dose PrEP

Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.

52nd International Liver Congress Roundup

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

Merck Applies to FDA for Approval of New HIV Med Doravirine

The new drug application is for doravirine as both an individual tablet and part of a combination tablet.

High Marks for Zepatier Among Those With Severe Chronic Kidney Disease

Merck’s hepatitis C treatment cured almost all those with stages 3 through 5 of chronic kidney disease in a VA database.
Advertisement
Treatment News
Features